ASCO 2023: Use of Radiation after Complete Response in PMBCL highlighting the IELSG47 Clinical Trial

ASCO 2023 rare lymphoma highlights: JACKPOT8, IELSG37, and mogamulizumab + CHOP in ATLПодробнее

Primary mediastinal B-cell lymphoma: Radiotherapy superfluous post-chemoimmunotherapyПодробнее

IELSG37 trial: Can radiotherapy be avoided in patients with PMBCL?Подробнее

Radiation Therapy Based on LUMINA Trial | Cynthia Ma, MD, PhD | ASCO22 Breast Cancer UpdatesПодробнее

Moffitt Cancer Center at ASCO 2023Подробнее

A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PTSПодробнее

ASCO 2023: Update on PROSPECT Trial Results from Dr. Alan VenookПодробнее

Highlights at ASCO 2023Подробнее

ASCO 2023 Highlights on nivolumab in advanced stage classic Hodgkin Lymphoma: the SWOG S1826 studyПодробнее

Flying Solo: Chemotherapy Without Radiation for Primary Central Nervous System LymphomaПодробнее

Boom-Boom Radiation as Bridging Therapy Prior to CAR-T for DLBCL | Christopher D'Angelo, MD | #ASH24Подробнее

The possibility of moving away from radiation therapy in pediatric patients with Hodgkin lymphomaПодробнее

Can Radiation Therapy Be Safely Skipped in Some Cancer Patients?Подробнее

Prof. Kieron Dunleavy | ASH 2017 | Key messages from the educational session on PMBCLПодробнее

This Revolutionary Treatment Kills Cancer From the Inside OutПодробнее

Varied Timing of IO Therapy in Patients With Stage III NSCLCПодробнее

ASCO 2023 - New Data Highlights Three Studies Showing The Impact Of Vitrakvi On Long-Term Efficacy &Подробнее

Priority Review Designation in PMBCL and 2017 SABCS and ASH Annual Meeting HighlightsПодробнее